Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlobalStem was a biotechnology company that specialized in providing standardized, high-quality tools and services for stem cell research. The company's product portfolio included human and murine stem cells, specialized cell culture media, and reagents such as mouse embryonic fibroblasts (MEFs) used as feeder layers. GlobalStem also provided contract research services, including cell line characterization, differentiation, and custom cell culture solutions. Their expertise focused on pluripotent stem cells, neural stem cells, and the development of optimized growth environments. In 2016, the company, then known as MTI-GlobalStem, was acquired by Thermo Fisher Scientific to strengthen its position in the cell biology and regenerative medicine markets. The acquisition integrated GlobalStem's specialized reagents and cell lines into Thermo Fisher's Life Technologies brand.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GlobalStem.